Christal M. M. Mickle - Jan 6, 2023 Form 3 Insider Report for KEMPHARM, INC (ZVRA)

Role
Chief Product Dev. Officer
Signature
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Christal M.M. Mickle
Stock symbol
ZVRA
Transactions as of
Jan 6, 2023
Transactions value $
$0
Form type
3
Date filed
1/10/2023, 08:19 PM
Next filing
Jan 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ZVRA Common Stock 12K Jan 6, 2023 Direct
holding ZVRA Common Stock 15.2K Jan 6, 2023 By Christal M.M. Mickle 2015 Gift Trust dtd 7/21/15, Travis C. Mickle as trustee
holding ZVRA Common Stock 9.82K Jan 6, 2023 By Travis C. Mickle 2015 Dynasty Trust dtd 7/21/15, as trustee
holding ZVRA Common Stock 96.2K Jan 6, 2023 By Mickle Holdings LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 1.25K $93.60 Direct F1
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 1.56K $327.20 Direct F1
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 1.25K $201.92 Direct F1
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 1.88K $56.80 Direct F1
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 1.88K $88.00 Direct F1
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 3.75K $42.56 Direct F2
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 2.25K $8.26 Direct F1
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 3.75K $5.98 Direct F1
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 48.4K $9.06 Direct F3
holding ZVRA Stock Option (right to buy) Jan 6, 2023 Common Stock 50.1K $7.17 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested.
F2 25% of the shares vested on February 6, 2020, 2021 and 2022, respectively, and the remaining 25% of the shares will vest on February 6, 2023, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.
F3 25% of the shares vested on August 20, 2022 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.
F4 25% of the shares will vest on February 1, 2023 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney